Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.41 |
| ▸ | CASP3 | P42574 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | DPP4 | P27487 | 1/20 | 0.36 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23999544 | 1.00 | HSD17B10 (0.41) | HSD17B10CASP3NPC1HRH3LMNA | |
| SCHEMBL694642 | 0.95 | ALDH1A1 (0.40) | HSD17B10CASP3NPC1HRH3HPGD | |
| SCHEMBL16826921 | 0.89 | HRH3 (0.40) | HSD17B10CASP3NPC1HRH3HPGD | |
| SCHEMBL8490471 | 0.80 | HSD17B10 (0.42) | HSD17B10CASP3NPC1HRH3LMNA | |
| SCHEMBL14938657 | 0.80 | CASP3 (0.43) | HSD17B10CASP3NPC1HRH3LMNA | |
| SCHEMBL2677782 | 0.80 | HSD17B10 (0.42) | HSD17B10CASP3NPC1HRH3LMNA | |
| SCHEMBL7362291 | 0.80 | HSD17B10 (0.42) | HSD17B10CASP3NPC1HRH3LMNA | |
| SCHEMBL31016714 | 0.80 | HSD17B10 (0.42) | HSD17B10CASP3NPC1HRH3LMNA | |
| SCHEMBL12084380 | 0.80 | HSD17B10 (0.42) | HSD17B10CASP3NPC1HRH3LMNA | |
| SCHEMBL4737546 | 0.79 | POLB (0.47) | SMN1; SMN2ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2015104602-A2 | A PROCESS FOR THE PREPARATION OF ANAGLIPTIN AND ITS INTERMEDIATES THEREOF | WOCKHARDT LIMITED (IN) | 2015-07-16 | — | — | WO | claimed |
| WO-2015150887-A1 | PROCESS FOR THE PREPARATION OF ANAGLIPTIN OR ITS SALTS | WOCKHARDT LIMITED (IN) | 2015-10-08 | — | — | WO | disclosed |
| WO-2015104602-A2 | A PROCESS FOR THE PREPARATION OF ANAGLIPTIN AND ITS INTERMEDIATES THEREOF | WOCKHARDT LIMITED (IN) | 2015-07-16 | — | — | WO | disclosed |
| CN-101312967-B | As 5-HT4Carbamate compounds of receptor agonists | THERAVANCE INC | 2011-08-24 | — | — | CN | disclosed |
| US-7514564-B2 | Substituted amine derivatives and methods of use | AMGEN INC. (US) | 2009-04-07 | — | — | US | disclosed |
| US-20090029939-A1 | Pre-organized tricyclic integrase inhibitor compounds | GILEAD SCIENCES, INC. | 2009-01-29 | — | — | US | disclosed |
| CN-101312967-A | As 5-HT4Carbamate compounds of receptor agonists | THERAVANCE INC (US) | 2008-11-26 | — | — | CN | disclosed |
| US-20080076738-A1 | Phosphonate Analogs Of Hiv Integrase Inhibitor Compounds | GILEAD SCIENCES, INC. | 2008-03-27 | — | — | US | disclosed |
| EP-1562933-B1 | SUBSTITUTED AMINE DERIVATIVES AND METHODS OF USE IN THE TREATMENT OF ANGIOGENESIS RELATED DISORDERS | AMGEN INC (US) | 2008-03-19 | — | — | EP | disclosed |
| CN-100374438-C | Pre-organized tricyclic integrase inhibitor compounds | GILEAD SCIENCES INC (US) | 2008-03-12 | — | — | CN | disclosed |
| US-20030203922-A1 | Substituted amine derivatives and methods of use | AMGEN INC. | 2003-10-30 | — | — | US | disclosed |
| US-20030195230-A1 | Substituted amine derivatives and methods of use | AMGEN INC. | 2003-10-16 | — | — | US | disclosed |
| CN-1053188-C | Quinolizinone type compounds | ABBOTT LAB (US) | 2000-06-07 | — | — | CN | disclosed |
| EP-0871628-A1 | QUINOLIZINONE TYPE COMPOUNDS | Abbott Laboratories (US) | 1998-10-21 | — | — | EP | disclosed |
| US-5726182-A | TREATMENT OF BACTERIAL INFECTIONS | ABBOTT LABORATORIES (US) | 1998-03-10 | — | — | US | disclosed |
| CN-1157611-A | Novel quinolone 5- (N-heterosubstituted amino) antimicrobial agents | PROCTER & GAMBLE (US) | 1997-08-20 | — | — | CN | disclosed |
| US-5599816-A | BACTERICIDE | ABBOTT LABORATORIES (US) | 1997-02-04 | — | — | US | disclosed |
| WO-1996039407-A1 | QUINOLIZINONE TYPE COMPOUNDS | ABBOTT LABORATORIES (US) | 1996-12-12 | — | — | WO | disclosed |
| CN-1137273-A | Quinolizinone type compounds | ABBOTT LAB (US) | 1996-12-04 | — | — | CN | disclosed |
| EP-0666853-A1 | ANTIMICROBIAL 5-HYDRAZINO-QUINOLONE DERIVATIVES | THE PROCTER & GAMBLE COMPANY (US) | 1995-08-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090029939-A1 | Pre-organized tricyclic integrase inhibitor compounds | MUS81, CDKL4, INTS6 | HSD17B10 1543/4885CASP3 2489/4885NPC1 1671/4885 |
| US-20030203922-A1 | Substituted amine derivatives and methods of use | MAOB, HNMT, FLT4 | HSD17B10 1947/4885CASP3 831/4885NPC1 782/4885 |
| US-20080076738-A1 | Phosphonate Analogs Of Hiv Integrase Inhibitor Compounds | TYMP, PNP, PIKFYVE | HSD17B10 1111/4885CASP3 3046/4885NPC1 1365/4885 |
| US-20030195230-A1 | Substituted amine derivatives and methods of use | MAOB, HNMT, FLT4 | HSD17B10 1947/4885CASP3 831/4885NPC1 782/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.